• 1
    Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68:9280-9290.
  • 2
    Junttila TT, Li G, Parsons K, Phillips GL, Sliwkowski MX. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat. 2011;128:347-356.
  • 3
    Barok M, Tanner M, Köninki K, Isola J. Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. Cancer Lett. 2011;306:171-179.
  • 4
    Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783-1791. Erratum in N Engl J Med. 2013;368:2442.
  • 5
    Lipscomb J, Gotay CC, Snyder CF. Patient-reported outcomes in cancer: a review of recent research and policy initiatives. CA Cancer J Clin. 2007;57:278-300.
  • 6
    Basch E, Iasonos A, McDonough T, et al. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol. 2006;7:903-909.
  • 7
    Basch E, Jia X, Heller G, et al. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst. 2009;101:1624-1632.
  • 8
    Agresta S, Hurvitz S, Lalla D, et al. Patient-reported outcomes (PROs) in HER2+ metastatic breast cancer (MBC) treated with T-DM1. Ann Oncol. 2010;21(suppl 8):v111345. Abstract 1117.
  • 9
    Hurvitz S, Dirix L, Kocsis J, et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2013;31:1157-1163. Erratum in J Clin Oncol. 2013;31:2977.
  • 10
    Brady MJ, Cella DF, Mo F, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol. 1997;15:974-986.
  • 11
    Yost KJ, Sorensen MV, Hahn EA, Glendenning GA, Gnanasakthy A, Cella D. Using multiple anchor- and distribution-based estimates to evaluate clinically meaningful change on the Functional Assessment of Cancer Therapy-Biologic Response Modifiers (FACT-BRM) instrument. Value Health. 2005;8:117-127.
  • 12
    Yost KJ, Eton DT. Combining distribution- and anchor-based approaches to determine minimally important differences: the FACIT experience. Eval Health Prof. 2005;28:172-191.
  • 13
    Chambers KK, McMillan SC. In: Frank-Stromborg M, Olson SJ, eds. Instruments for Clinical Health-Care Research. ed 2. Boston: Jones & Bartlett Publishers; 1997:487-497.
  • 14
    Gwede CK, James JL, Zachariah B, et al. Quality of life (QOL), bowel symptoms and function assessments in patients undergoing chemoradiation for anal or rectal cancer: RTOG 0315. Presented at: 14th Annual Congress of the International Society for Quality of Life Research, Toronto, Canada, October 10-13, 2007. Abstract 1597.
  • 15
    Eton DT, Cella D, Yost KJ, et al. A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J Clin Epidemiol. 2004;57:898-910.
  • 16
    Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics. 1982;38:29-41.
  • 17
    Littell RC, Milliken GA, Stroup WW, et al. SAS for Mixed Models. 2nd ed. Cary, NC: SAS Institute Inc; 2006.
  • 18
    Blyth CR, Still HA. Binomial confidence intervals. J Am Stat Assoc. 1983;78:108-116.
  • 19
    Casella G. Refining binomial confidence intervals. Can J Stat. 1986;14:113-129.
  • 20
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-748.
  • 21
    Cella D, Wang M, Wagner L, Miller K. Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: results from Eastern Cooperative Oncology Group Study 2100 (E2100). Breast Cancer Res Treat. 2011;130:855-861.
  • 22
    Corey-Lisle PK, Peck R, Mukhopadhyay P, et al. Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer. Cancer. 2012;118:461-468.
  • 23
    Sherrill B, Di Leo A, Amonkar MM, et al. Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer. Curr Med Res Opin. 2010;26:767-775.
  • 24
    Fairclough L. Design and Analysis of Quality of Life Studies in Clinical Trials. ed 2. Boca Raton, FL: Taylor & Francis Group; 2010.
  • 25
    Siddiqui O, Hung HM, O'Neill R. MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets. J Biopharm Stat. 2009;19:227-246.
  • 26
    Osoba D, Hsu MA, Copley-Merriman C, et al. Stated preferences of patients with cancer for health-related quality-of-life (HRQOL) domains during treatment. Qual Life Res. 2006;15:273-283.
  • 27
    White CB, Smith ML, Abidoye O, Lalla D. Examining patient treatment choices involving efficacy, toxicity, and cost tradeoffs in the metastatic breast cancer setting. Cancer Res. 2012;72(24 suppl):542s. Abstract P6-09-11.